The University of Iowa and UCLA have launched a pioneering study, SAYSTOP, to explore a strategy for discontinuing antibiotics after symptom resolution, aiming to tackle the global health threat of antibiotic resistance.
In a significant stride towards tackling the global health crisis of antibiotic resistance, The University of Iowa, in collaboration with Olive View Medical Center, University of California, Los Angeles, has introduced an innovative solution through its latest research initiative. The Study of Antibiotics You Stop for Treatment Of Pyelonephritis (SAYSTOP) aims to explore a patient-centered strategy for discontinuing antibiotics upon the resolution of symptoms in acute, uncomplicated pyelonephritis, a form of urinary tract infection (UTI).
To facilitate this groundbreaking study, the institutions have partnered with TrialX, a clinical research and space health informatics company, to develop the SAYSTOP Study App. This digital tool is designed to help participants monitor their antibiotic intake and symptoms, thereby enabling precise data collection to understand antibiotic usage patterns better.
Antibiotic resistance poses a daunting challenge to global healthcare, fueling the urgency to address the overuse and misuse of antibiotics meticulously. Dr. Brett Faine from the University of Iowa and Dr. David Talan from UCLA, co-principal investigators of the study, are examining the safety implications of patients discontinuing antibiotics as soon as they experience symptom relief versus the traditional approach of completing the prescribed antibiotic course.
The SAYSTOP Study stands at the intersection of technology and healthcare innovation, with TrialX providing a state-of-the-art mobile application for seamless and efficient remote data collection. Participants will be provided with medications in separate blister packs, facilitating a controlled environment for the study while enabling real-time symptom and dosage tracking.
Dr. Faine articulated the pivotal role of technology in addressing clinical trial challenges and asserted the project’s potential in deriving actionable insights to curb antibiotic resistance. Echoing this sentiment, Paul Donnelly, CSO of TrialX, highlighted the app’s significance in advancing the fight against antibiotic resistance. Leveraging decentralized clinical trial technology, the SAYSTOP Study App aims to empower researchers with streamlined data collection processes, fostering the discovery of impactful healthcare strategies.
Available for both iOS and Android devices, the SAYSTOP Study App signifies the collaborative effort among clinical research professionals, technologists, and healthcare providers to confront a critical public health issue. By integrating technological advancements into clinical research, this initiative sets a precedent for future endeavors aiming to enhance patient outcomes and propel medical innovation.
TrialX’s mission to facilitate One Billion Health Research Contributions is further exemplified through this partnership, underscoring the company’s commitment to bridging the gap between patients and researchers. With a portfolio of tools including a patient recruitment management platform, a remote research data collection platform, and an online talk show, TrialX continues to be at the forefront of medical research innovation.
The SAYSTOP study underscores the essential role of interdisciplinary collaboration in addressing global health challenges. By harnessing technology’s potential in clinical research, the initiative paves the way for developing sustainable strategies against antibiotic resistance, ultimately contributing to improved healthcare outcomes worldwide.
For more information about the study and to participate, interested individuals are encouraged to visit the University of Iowa’s website, marking the first step towards a collective effort in combating antibiotic resistance through informed and patient-centered healthcare strategies.